# Bukwang Pharmaceutical clinical trials: 34 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 34 trials with Bukwang Pharmaceutical as lead sponsor, 1 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Bukwang Pharmaceutical: 34 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/bukwang-pharmaceutical

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 34
- Recruiting or not yet: 1
- Read on: November 19, 2026

## Trials

The 25 newest of 34, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| August 24, 2026 | NCT07781293 | Study of Lurasidone as Adjunctive Treatment in Patients With Major Depressive Disorder With Inadequate Response to Antidepressant... | Bukwang Pharmaceutical | Phase 3 | Not yet recruiting | Major Depressive Disorder (MDD), Major Depressive Disorder With Psychotic Features | 364 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07781293) |
| August 28, 2023 | NCT06014853 | A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of SOL-804 in Healthy Male Subjects | Bukwang Pharmaceutical | Phase 1 | Completed | Prostate Cancer | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06014853) |
| May 18, 2021 | NCT04891302 | The Proof of Concept Phase 2 Study to Evaluate the Safety and Efficacy of Clevudine in Patients With Mild and Moderate COVID-19 | Bukwang Pharmaceutical | Phase 2 | Completed | COVID-19 | 104 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04891302) |
| May 7, 2020 | NCT04377945 | Study in Parkinson's Disease Patients With Dyskinesia With Combinations of JM-010 and Its Individual Components | Bukwang Pharmaceutical | Phase 2 | Terminated | Dyskinesias, Parkinson Disease | 41 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04377945) |
| April 15, 2020 | NCT04347915 | The Phase 2 Study to Evaluate the Safety and Efficacy of Clevudine in Patients With Moderate COVID-19 | Bukwang Pharmaceutical | Phase 2 | Completed | COVID-19 | 64 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04347915) |
| March 14, 2018 | NCT03465787 | A 6-week Study to Evaluate the Efficacy and Safety of Lurasidone HCL in Acutely Psychotic Patients With Schizophrenia | Bukwang Pharmaceutical | Phase 3 | Completed | Schizophrenia | 210 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03465787) |
| March 17, 2016 | NCT02711969 | A Study of Apatinib Mesylate (YN968D1) 1,000mg in Gastric Cancer Patient Failed to Standard Treatment | Bukwang Pharmaceutical | Phase 1 | Completed | Gastric Cancer | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02711969) |
| May 8, 2015 | NCT02439203 | Efficacy and Safety of JM-010 in PD With Levodopa-Induced Dyskinesia | Bukwang Pharmaceutical | Phase 2 | Completed | Parkinson's Disease, Levodopa Induced Dyskinesia (LID) | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02439203) |
| June 21, 2012 | NCT01624779 | Intrathecal Transplantation Of Autologous Adipose Tissue Derived MSC in the Patients With Spinal Cord Injury | Bukwang Pharmaceutical | Phase 1 | Completed | Spinal Cord Injury | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01624779) |
| April 20, 2012 | NCT01581242 | A Clinical Trial to Investigate the Pharmacokinetic Drug-drug Interaction of Clevudine and Adefovir Dipivoxil After Oral Administration in... | Bukwang Pharmaceutical | Phase 1 | Completed | Healthy | 42 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01581242) |
| January 11, 2012 | NCT01507922 | Comparative Efficacy and Safety of Fenoverine | Bukwang Pharmaceutical | Phase 4 | Completed | Irritable Bowel Syndrome | 186 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01507922) |
| December 24, 2010 | NCT01266005 | A Study to Compare and Evaluate Intrahepatic cccDNA Reduction After Administrating Clevudine or Entecavir in the Chronic HBV Patients | Bukwang Pharmaceutical | Phase 4 | Terminated | Chronic Hepatitis B | 75 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01266005) |
| December 21, 2010 | NCT01264367 | A Study to Evaluate the Efficacy and Safety of Clevudine and Peg-interferon in Sequence Compared With Clevudine Alone in the Patients With... | Bukwang Pharmaceutical | Phase 4 | Completed | HBeAg(+) Chronic Hepatitis B | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01264367) |
| December 21, 2010 | NCT01264354 | An Open Study to Evaluate the Efficacy, Safety of Clevudine Monotherapy or Adefovir and Clevudine Combination in Patients With Chronic... | Bukwang Pharmaceutical | Phase 4 | Completed | Chronic Hepatitis B | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01264354) |
| December 21, 2010 | NCT01264133 | A Study With Clevudine Monotherapy or Adefovir and Clevudine Combination in Patients With Chronic Hepatitis B | Bukwang Pharmaceutical | Phase 4 | Terminated | Chronic Hepatitis B | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01264133) |
| December 21, 2010 | NCT01264107 | An Open Study to Evaluate the Sustained Effect in Patients Showing Virological Responses With Muscle-related Symptom of Chronic Hepatitis B... | Bukwang Pharmaceutical | Observational | Completed | Chronic Hepatitis B | 37 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01264107) |
| December 21, 2010 | NCT01264094 | A Study to Evaluate the Efficacy and the Change of sAg Levels in Chronic Hepatitis B Patients Receiving Clevudine Treatment Over the Long... | Bukwang Pharmaceutical | Phase 4 | Terminated | Chronic Hepatitis B | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01264094) |
| December 20, 2010 | NCT01263002 | A Study With Clevudine Monotherapy or Adefovir and Clevudine Combination in Proportion to Roadmap Concept in Patients With HBV... | Bukwang Pharmaceutical | Phase 4 | Completed | Hepatitis B Associated Hepatocellular Carcinoma | 33 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01263002) |
| December 16, 2010 | NCT01261143 | Randomized, Double-blind Study to Assess the Efficacy and Safety of α-lipoic Acid Versus BK-C-0701 in Subjects With Diabetic Neuropathy | Bukwang Pharmaceutical | Phase 3 | Completed | Diabetic Neuropathies | 164 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01261143) |
| December 13, 2010 | NCT01258699 | A Study Comparing the Pharmacokinetics of BK-C-0701 320mg, 480mg and Thiocacid HR Tab 600mg in Healthy Adult Male Subjects | Bukwang Pharmaceutical | Phase 1 | Completed | Healthy Adult Male | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01258699) |
| December 13, 2010 | NCT01258686 | Clinical Study With Silymarin in the Patients With Chronic Hepatitis C Infection Who Failed Conventional Antiviral Therapy | Bukwang Pharmaceutical | Phase 3 | Completed | Hepatitis C | 53 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01258686) |
| May 6, 2008 | NCT00672867 | A Pilot Study to Evaluate the Safety and Efficacy of Clevudine or Adefovir Patients With LC-B | Bukwang Pharmaceutical | Phase 3 | Completed | Patients With LC-B | 102 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00672867) |
| March 21, 2008 | NCT00641082 | A Double-Blind Randomized Clinical Trial Comparing the Safety and Antiviral Activity of 48-week Clevudine and Adefovir Dipivoxil in... | Bukwang Pharmaceutical | Phase 4 | Completed | HBeAg(-) Chronic Hepatitis B With Compensated Liver Function | 43 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00641082) |
| November 15, 2007 | NCT00558818 | Long-term Study With Clevudine | Bukwang Pharmaceutical | Phase 4 | Completed | Chronic Hepatitis B | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00558818) |
| November 15, 2007 | NCT00558493 | Switching Study From Lamivudine to Clevudine in the Chronic Hepatitis B Patients | Bukwang Pharmaceutical | Phase 4 | Completed | Chronic Hepatitis B | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00558493) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 5 |
| Phase 2 | 7 |
| Phase 3 | 9 |
| Phase 4 | 11 |
| Observational | 2 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 23 |
| Terminated | 10 |
| Not yet recruiting | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Hepatitis B | 9 |
| Hepatitis B, Chronic | 8 |
| Dyskinesias | 2 |
| Parkinson Disease | 2 |
| COVID-19 | 2 |
| Depressive Disorder, Major | 1 |
| Spinal Cord Injuries | 1 |
| Schizophrenia | 1 |
| Stomach Neoplasms | 1 |
| Diabetic Neuropathies | 1 |
| Hepatitis C | 1 |
| Irritable Bowel Syndrome | 1 |
| Abdominal Pain | 1 |
| Prostatic Neoplasms | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Pharmaceutical companies in the United States](https://specstream.ai/data/businesses/pharmaceutical-companies/united-states)
- [Bars in the United States](https://specstream.ai/data/businesses/bars/united-states)
- [Veterans hospitals in the United States](https://specstream.ai/data/businesses/veterans-hospitals/united-states)
- [Restaurant equipment suppliers in the United States](https://specstream.ai/data/businesses/restaurant-equipment-suppliers/united-states)
- [Mortgage lenders in the United States](https://specstream.ai/data/businesses/mortgage-lenders/united-states)
- [Home network installers in the United States](https://specstream.ai/data/businesses/home-network-installers/united-states)
